Key facts
- NHS approves AbbVie's ovarian cancer drug Elahere.
- Elahere will be available for patients with platinum-resistant ovarian cancer.
The National Health Service (NHS) has granted approval for AbbVie's ovarian cancer drug, Elahere, to be made available. This decision is a crucial development for patients suffering from platinum-resistant ovarian cancer, as it introduces a new therapeutic option into their treatment regimens. The approval signifies a positive step forward in the ongoing efforts to combat this challenging form of cancer and improve patient outcomes.